8 studies found for:    BMS-663513
Show Display Options
RSS Create an RSS feed from your search for:
BMS-663513
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Recruiting Combination Study of Urelumab and Rituximab in Patients With B-cell Non-Hodgkins Lymphoma or CLL
Condition: B-Cell Malignancies
Interventions: Biological: Urelumab;   Biological: Rituxan
2 Recruiting Safety, Tolerability, Pharmacokinetics, and Immunoregulatory Study of Urelumab (BMS-663513) in Subjects With Advanced and/or Metastatic Solid Tumors and Relapsed/Refractory B-cell Non-Hodgkin's Lymphoma
Condition: Cancer - Solid Tumors and B-Cell Non-Hodgkin's Lymphoma
Intervention: Drug: Urelumab (BMS-663513)
3 Recruiting Combination Study of Urelumab and Cetuximab in Patients With Advanced/Metastatic Colorectal Cancer or Advanced/Metastatic Head and Neck Cancer
Conditions: Colorectal Cancer;   Head and Neck Cancer
Interventions: Biological: Urelumab;   Biological: Cetuximab
4 Terminated A Study of BMS-663513 in Combination With Chemoradiation in Subjects With Non Small Cell Lung Carcinoma (NSCLC)
Condition: Non Small Cell Lung Cancer
Intervention: Drug: BMS-663513
5 Terminated A Study of BMS-663513 Administered in Combination With Chemotherapy to Subjects With Advanced Solid Malignancies
Condition: Advanced Solid Malignancies
Intervention: Drug: BMS-663513
6 Terminated Study of BMS-663513 in Patients With Advanced Cancer
Condition: Tumors
Intervention: Drug: BMS-663513
7 Withdrawn Combination of Anti-CD137 & Ipilimumab in Patients With Melanoma
Condition: Melanoma
Interventions: Drug: AntiCD137;   Drug: Ipilimumab
8 Completed Phase II, 2nd Line Melanoma - RAND Monotherapy
Condition: Melanoma
Intervention: Drug: Anti-CD137 (4-1BB) (BMS-663513)

Indicates status has not been verified in more than two years